Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2021-05-17 Investor Presentation
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 17, 2021, which is a Current Report under the Securities Exchange Act of 1934. The content focuses on Regulation FD Disclosure about upcoming investor presentations (Corporate Presentation and R&D Day Presentation) that are attached as exhibits. It explicitly states that these presentations will be used for investor relations and are available on the company's website. There is no detailed financial data or comprehensive report content such as an annual or quarterly report. The document is primarily an announcement of presentations and disclosures rather than the presentations themselves or a financial report. Therefore, this fits the category of an Investor Presentation (IP) filing type, as it relates to detailed presentations for investors focusing on financials, strategy, and market position.
2021-05-17 English
SC 13D/A
Major Shareholding Notification
2021-05-10 English
PRE 14C
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14C Information Statement filed with the SEC, pursuant to Section 14(c) of the Securities Exchange Act of 1934. It is a preliminary information statement informing stockholders of a stockholder action by written consent approving the issuance of shares related to an asset purchase agreement. The document explicitly states it is not a proxy solicitation and no vote is requested. The content includes detailed transaction terms, parties involved, and regulatory compliance information. This type of filing is used to inform shareholders of corporate actions without a meeting and is classified as a Proxy Solicitation & Information Statement (PSI). It is not an annual report, earnings release, or other financial report, but rather a communication to shareholders about a specific corporate action requiring their information but not a vote.
2021-05-10 English
FORM 10-Q FOR PERIOD ENDING MARCH 31, 2021
Interim / Quarterly Report Q3 2021
2021-05-10 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content details an amendment to an Asset Purchase Agreement (APA) involving acquisition of assets and contingent stock consideration. It includes specifics about the transaction, approvals by the Board of Directors, and references to exhibits such as the amendment and a press release. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a material definitive agreement and related amendments, which fits the category of Capital/Financing Update (CAP) as it involves changes in capital structure and financing terms related to the acquisition. The length (12,677 characters) and detailed content confirm it is not a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2021-05-10 English
PRE 14C
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed pursuant to Section 14(c) of the Securities Exchange Act of 1934. It is a detailed information statement provided to stockholders regarding a transaction involving the issuance of shares in connection with an Asset Purchase Agreement. The document explicitly states it is an Information Statement and not a proxy solicitation, and it includes detailed descriptions of the transaction, parties involved, and terms of the agreement. This type of filing is used to inform shareholders of corporate actions without requiring a vote, fitting the definition of a Proxy Solicitation & Information Statement (PSI). The document is lengthy (15,000 characters) and contains substantive information, not merely an announcement or a brief summary. Therefore, the correct classification is PSI with high confidence.
2021-05-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.